Eileen M Barry
Ph.D.
|
| Academic Title:
Associate Professor |
| Primary Appointment:
Medicine |
| Secondary Appointments:
Medical and Research Technology, Microbiology and Immunology |
|
ebarry@medicine.umaryland.edu |
| Location:
HSF-II,
S363 |
| Phone:
(410) 706-3702 |
|
Research Interests
Dr. Barry's research in the Center for Vaccine Development focuses on the development of vaccines against enteric pathogens, including Shigella and enterotoxigenic E. coli (ETEC), that are responsible for significant morbidity and mortality throughout the world. Target populations include children in less developed counties who suffer the largest burden as well as travelers to endemic regions and deployed military personnel. These pathogens cause infection following ingestion and our strategy is to develop live attenuated strains that are delivered via the oral route. We have constructed live attenuated vaccine candidates of Shigella which have advanced to Phase I clinical trials where they have been demonstrated to be safe and immunogenic. The attenuated bacteria are also used as live vectors for the expression and delivery of antigens from heterologous pathogens. We have constructed a vaccine composed of attenuated Shigella expressing critical ETEC antigens. This multivalent vaccine is currently in Phase I clinical studies.
An additional area of research is the development of vaccines against Francisella tularensis, a pathogen of interest for bioterror countermeasure development. Vaccine candidates have been engineered with specific mutations and attenuation as well as immunogenicity are currently being evaluated.
Laboratory projects include the study of basic mechanisms of pathogenesis of Shigella, ETEC and Francisella, antigen identification, host responses, and model development. Techniques include molecular engineering, electron microscopy, zero gravity organoid models, and in vitro organ culture.
Publications
Selected Publications
Ramirez, K., E.M. Barry, Jeffrey Ulmer, Richard Stout, Myron M. Levine, Marcela F. Pasetti. 2008. Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen. Human Gene Therapy. 19:522-531.
Cole, L.E., A. Santiago, E. Barry, T. J. Kang, K. A. Shirey, Z. J. Roberts, K. L. Elkins, A. S. Cross, and S. N. Vogel. 2008. The macrophage proinflammatory response to Francisella tularensis LVS requires coordination of multiple signaling pathways. J. Immunol., 180:6885.
Pasetti, M.F. , A. Resendiz-Albor, K. Ramirez, R. Stout, M. Papania , R. J. Adams, F. P. Polack, B. J. Ward, D. Burt , S. Chabot, J. Ulmer, E. M. Barry and M. M. Levine. 2007. Heterologous prime boost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques. Clinical Pharmacology and Therapeutics, 82:672-85.
Cole, L.E., Shirey, K.A., Barry, E.M., Santigao, A., Rallabhandi, P., Elkins, K.L., Puche, A., Michalek, S.M., and Vogel, S.N. 2007. TLR2-Mediated Signaling Requirements for Francisella tularensis LVS Infection of Murine Macrophages. J. Immunology, 75(8): 4127-37.
Kotloff, KL., J.K. Simon, M.F. Pasetti, M.B. Sztein, S. Wooden, S. Livio, W.C. Blackwelder, E.M. Barry, J.P. Nataro, W.D. Picking, and M.M. Levine. 2007. Safety and immunogenicity of CVD 1208S, a live, oral Shigella flexneri 2a vaccine grown on animal free media. Human Vaccines, 3:268-275.
Levine, M.M., K.L. Kotloff, E. M. Barry, M.F. Pasetti, and M.B. Sztein. 2007. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nature Reviews Microbiogy, 5(7):540-553.
Capozzo, A.V., Ramirez, K., Polo, J.M., Ulmer, J., Barry, E.M., Levine, M.M., Pasetti, M.F. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. 2006. J Immunol. 176(9):5671-81.
Eileen M. Barry, Jin Wang, Tao Wu, Tamar Davis and Myron M. Levine. Immunogenicity of Multivalent Shigella-ETEC Candidate Vaccine Strains in a Guinea Pig Model. 2006. Vaccine 24:3727-34.
Song, MK, CJ Vindurampulle, AV Capozzo, J. Ulmer, JM Polo, MF Pasetti, EM Barry, and MM Levine. 2005. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J. Virol. 79:9854-9861.
Kotloff, KL., M.F. Pasetti, E.M. Barry, J.P. Nataro, S.S. Wasserman, M.B. Sztein, W.D. Picking, and M.M. Levine. 2004. Deletion of the Shigella Enterotoxin Genes Further Attenuates Shigella flexneri 2a bearing Guanine Auxotrophy in a Phase I Trial of CVD 1204 and CVD 1208. JID, 190:1745-1754.
Vindurampulle, C.J., L. Cuberos, E.M. Barry, M.F. Pasetti, and M.M. Levine. 2004. Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy. Vaccine, 22:3744-3750.
Pasetti, M. F., E. M. Barry, G. Losonsky, M. Singh, S. M. Medina-Moreno, J. M. Polo, J. Ulmer, H. Robinson, M. B. Sztein, and M.M. Levine. 2003. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a Strains Mucosally Deliver DNA Vaccines Encoding Measles Virus Hemagglutinin, Inducing Specific immune responses and Protection in Cotton Rats. J. Virol. 77: 5209-5217
Kotloff, KL., M.F. Pasetti, E.M. Barry, J.P. Nataro, S.S. Wasserman, M.B. Sztein, W.D. Picking, and M.M. Levine. 2004. Deletion of the Shigella Enterotoxin Genes Further Attenuates Shigella flexneri 2a bearing Guanine Auxotrophy in a Phase I Trial of CVD 1204 and CVD 1208. JID, 190:1745-1754.
Altboum, Z, Myron M. Levine, James E. Galen, and Eileen M. Barry. 2003. Characterization and Immunogencity of Coli Surface Antigen 4 (CS4) from Enterotoxigenic E. coli when it is Expressed in Shigella flexneri Live Vector Strain. Submitted Infect. Immun. Infect. and Immun.
71:1352-1360.
Barry, E.M., Z. Altboum, G. Losonsky, and M.M. Levine. 2003. Immune Responses Elicited Against Multiple Enterotoxigenic Escherichia coli Fimbriae and Mutant LT expressed in Attenuated Shigella Vaccine Strains. Vaccine. 21:333-340
Altboum, Z., E.M. Barry, G. Losonsky, and M.M. Levine. 2001. Attenuated Shigella flexneri 2a AguaBA strain CVD 1204-expressing ETEC CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and enterotoxigenic Eschericia coli infection. Infect. And Immun. 69:3150-3158.
Koprowski II, H., M. M. Levine, R. Anderson, G. Losonsky, M. Pizza, and E. M. Barry. 2000. Attenuated Shigella flexneri 2a Vaccine Strain CVD 1204 Expressing Colonization factor Antigen I (CFA/I) and Mutant Human Heat Labile Toxin of Enterotoxigenix Escherichia coli. Infect. and Immun. 68:4884-4892.
Barry, E.M., O. Gomez-Duarte, S. Chatfield, R. Rappuoli, J. Galen, G. Losonsky and M.M. Levine. 1996. Expression and Antigenicity of Pertussis Toxin S1 Subunit-Tetanus Toxin Fragment C Fusions in the S. typhi Vaccine Strain CVD 908. Infect. and Immun. 64:4172-4181.
Faculty members:
Click here to update your contact information and create a profile.
|